Asset monetisation, sales uptick in US key triggers for Glenmark Pharma

The India business is expected to post double digit growth in FY22

Revenue growth reported by Glenmark Pharma in the December quarter was entirely due to the Indian operations and higher active pharmaceutical ingredient (API) sales.

Supported by higher sales of Covid drug Fabiflu, growth in the domestic market (31 per cent of sales) was up 11 per cent as compared to the year-ago period. While Fabiflu sales have come down on a sequential basis, the company gained market share in key therapies and the base business outperformed the sector in the quarter. API sales registered growth of 22 per cent YoY. This helped the company post consolidated sales growth of just under